Diabetes Metab J.  2012 Dec;36(6):443-451. 10.4093/dmj.2012.36.6.443.

Relationships between Brachial-Ankle Pulse Wave Velocity and Peripheral Neuropathy in Type 2 Diabetes

• Ha BK
• Kim BG
• Kim DH
• Lee SI
• Jung SM
• Park JY
• Lee CW
• Kim SS
• Kim BH
• Kim IJ

• KMID: 2174370
• DOI: http://doi.org/10.4093/dmj.2012.36.6.443

Abstract

BACKGROUND
Brachial-ankle pulse wave velocity (baPWV) is known to be a good surrogate marker of clinical atherosclerosis. Atherosclerosis is a major predictor for developing neuropathy. The goal of this study was to determine the relationship between baPWV and diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes.
METHODS
A retrospective cross-sectional study was conducted involving 692 patients with type 2 diabetes. The correlation between increased baPWV and DPN, neurological symptoms, and neurological assessment was analyzed. DPN was examined using the total symptom score (TSS), ankle reflexes, the vibration test, and the 10-g monofilament test. DPN was defined as TSS > or =2 and an abnormal neurological assessment. Data were expressed as means+/-standard deviation for normally distributed data and as median (interquartile range) for non-normally distributed data. Independent t-tests or chi-square tests were used to make comparisons between groups, and a multiple logistic regression test was used to evaluate independent predictors of DPN. The Mantel-Haenszel chi-square test was used to adjust for age.
RESULTS
Patients with DPN had higher baPWV and systolic blood pressure, and were more likely to be older and female, when compared to the control group. According to univariate analysis of risk factors for DPN, the odds ratio of the baPWV > or =1,600 cm/sec was 1.611 (95% confidence interval [CI], 1.072 to 2.422; P=0.021) and the odds ratio in female was 1.816 (95% CI, 1.195 to 2.760; P=0.005).
CONCLUSION
Increased baPWV was significantly correlated with peripheral neuropathy in patients with type 2 diabetes.

Keyword

Brachial-ankle pulse wave velocity; Diabetes mellitus, type 2; Diabetic peripheral neuropathy

MeSH Terms

Animals
Ankle
Atherosclerosis
Biomarkers
Blood Pressure
Cross-Sectional Studies
Diabetes Mellitus, Type 2
Female
Humans
Logistic Models
NAD
Odds Ratio
Peripheral Nervous System Diseases
Pulse Wave Analysis
Reflex
Retrospective Studies
Risk Factors
Vibration
NAD

Reference

1. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med. 1998. 15:508–514.

2. Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L, Boulton AJ. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care. 2002. 25:2010–2015.

3. Pascuzzi RM. Peripheral neuropathies in clinical practice. Med Clin North Am. 2003. 87:697–724.

4. Kumar S, Fernando DJ, Veves A, Knowles EA, Young MJ, Boulton AJ. Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes Res Clin Pract. 1991. 13:63–67.

5. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care. 1994. 17:557–560.

6. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003. 26:1553–1579.

7. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III). National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003. 52:1210–1214.

8. O'Neal DN, Dragicevic G, Rowley KG, Ansari MZ, Balazs N, Jenkins A, Best JD. A cross-sectional study of the effects of type 2 diabetes and other cardiovascular risk factors on structure and function of nonstenotic arteries of the lower limb. Diabetes Care. 2003. 26:199–205.

9. Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. J Hypertens Suppl. 1999. 17:S41–S44.

10. van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS, Hoeks AP, van der Kuip DA, Hofman A, Witteman JC. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke. 2001. 32:454–460.

11. Aso K, Miyata M, Kubo T, Hashiguchi H, Fukudome M, Fukushige E, Koriyama N, Nakazaki M, Minagoe S, Tei C. Brachialankle pulse wave velocity is useful for evaluation of complications in type 2 diabetic patients. Hypertens Res. 2003. 26:807–813.

12. Kubo T, Miyata M, Minagoe S, Setoyama S, Maruyama I, Tei C. A simple oscillometric technique for determining new indices of arterial distensibility. Hypertens Res. 2002. 25:351–358.

13. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R, Safar M. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens. 2002. 15:1101–1108.

14. Yokoyama H, Shoji T, Kimoto E, Shinohara K, Tanaka S, Koyama H, Emoto M, Nishizawa Y. Pulse wave velocity in lower-limb arteries among diabetic patients with peripheral arterial disease. J Atheroscler Thromb. 2003. 10:253–258.

15. Bastyr EJ 3rd, Price KL, Bril V. MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005. 27:1278–1294.

16. Suzuki E, Kashiwagi A, Nishio Y, Egawa K, Shimizu S, Maegawa H, Haneda M, Yasuda H, Morikawa S, Inubushi T, Kikkawa R. Increased arterial wall stiffness limits flow volume in the lower extremities in type 2 diabetic patients. Diabetes Care. 2001. 24:2107–2114.

17. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. 2000. 43:957–973.

18. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010. 33:2285–2293.

19. Donaghue VM, Giurini JM, Rosenblum BI, Weissman PN, Veves A. Variability in function measurements of three sensory foot nerves in neuropathic diabetic patients. Diabetes Res Clin Pract. 1995. 29:37–42.

20. Ziegler D, Mayer P, Wiefels K, Gries FA. Assessment of small and large fiber function in long-term type 1 (insulin-dependent) diabetic patients with and without painful neuropathy. Pain. 1988. 34:1–10.

21. Holland NR, Crawford TO, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann Neurol. 1998. 44:47–59.

22. Kennedy WR, Said G. Sensory nerves in skin: answers about painful feet? Neurology. 1999. 53:1614–1615.

23. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001. 37:1236–1241.

24. Kim YK, Kim D. The relation of pulse wave velocity with framingham risk score and SCORE risk score. Korean Circ J. 2005. 35:22–29.

25. Kim HJ, Nam JS, Park JS, Cho M, Kim CS, Ahn CW, Kwon HM, Hong BK, Yoon YW, Cha BS, Kim KR, Lee HC. Usefulness of brachial-ankle pulse wave velocity as a predictive marker of multiple coronary artery occlusive disease in Korean type 2 diabetes patients. Diabetes Res Clin Pract. 2009. 85:30–34.

26. Lee SW, Yun KW, Yu YS, Lim HK, Bae YP, Lee BD, Kim BH, Lee CW. Determinants of the brachial-ankle pulse wave velocity (baPWV) in patients with type 2 diabetes mellitus. J Korean Endocr Soc. 2008. 23:253–259.

27. Kim YK, Lee MY, Rhee MY. A simple oscillometric measurement of pulse wave velocity: comparison with conventional tonometric measurement. Korean J Med. 2004. 67:597–606.

28. O'Rourke M. Mechanical principles in arterial disease. Hypertension. 1995. 26:2–9.

29. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997. 336:973–979.

30. Smith JK, Dykes R, Douglas JE, Krishnaswamy G, Berk S. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA. 1999. 281:1722–1727.

31. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K, Gries FA. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995. 38:1425–1433.

32. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, Tritschler HJ, Mehnert H. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999. 31:171–179.

33. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997. 20:369–373.

34. Tavee J, Zhou L. Small fiber neuropathy: a burning problem. Cleve Clin J Med. 2009. 76:297–305.

35. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004. 27:1458–1486.

36. Mason J, O'Keeffe C, McIntosh A, Hutchinson A, Booth A, Young RJ. A systematic review of foot ulcer in patients with type 2 diabetes mellitus. I: prevention. Diabet Med. 1999. 16:801–812.

37. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care. 2002. 25:2048–2052.

38. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994. 17:1281–1289.